title: Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
abstract: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers.
  
  
  
  We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB).
  
  
  
  We included 375 DLB patients, 164 Parkinson's disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid-beta42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) values were dichotomized as abnormal or normal according to locally available cut-off values. A CSF AD profile was defined as abnormal Aβ42 combined with abnormal t-tau and/or p-tau.
  
  
  
  A substantial proportion of DLB patients had abnormal values for CSF Aβ42, t-tau, and p-tau, while abnormal values were uncommon in PD without dementia. Patients with PDD had values in between. A CSF AD profile was observed in 25% of DLB patients, compared with only 9% of PDD and 3% of PD without dementia. Within DLB, patients with a CSF AD profile were older, more often female, performed worse on the Mini-Mental State Examination, and had shorter disease duration compared with patients with normal CSF.
  
  
  
  A CSF AD profile is more common in DLB compared with PDD and PD, and is associated with more severe cognitive impairment in DLB.
authors: Department of Neurology & Alzheimer Centre, VU University Medical Center, Amsterdam, The Netherlands.
authors: Inger
authors: I
authors: van Steenoven
authors: Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden.|Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
authors: Dag
authors: D
authors: Aarsland
authors: Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors: Daniel
authors: D
authors: Weintraub
authors: Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
authors: Elisabet
authors: E
authors: Londos
authors: Neuropsychology Unit and Geriatric Day Hospital (Strasbourg Resource and Research Memory Centre, CMRR) University Hospital of Strasbourg and ICube Laboratory, FMTS, University of Strasbourg and CNRS, Strasbourg, France.
authors: Frédéric
authors: F
authors: Blanc
authors: Department of Neurology & Alzheimer Centre and Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
authors: Wiesje M
authors: WM
authors: van der Flier
authors: Neurochemistry Lab and Biobank, Department of Clinical Chemistry, VU University Medical Center Amsterdam, The Netherlands.
authors: Charlotte E
authors: CE
authors: Teunissen
authors: Paracelsus-Elena-Klinik, Kassel and University Medical Center, Department of Neurosurgery and Institute of Neuropathology, Göttingen, Germany.
authors: Brit
authors: B
authors: Mollenhauer
authors: Department of Neurology, Akershus University Hospital and Faculty of Medicine, University of Oslo, Norway.
authors: Tormod
authors: T
authors: Fladby
authors: Department of Neurology, University Medical Centre, Ljubljana, Slovenia.
authors: Milica G
authors: MG
authors: Kramberger
authors: Department of Neuroscience and Imaging and Clinical Science, and Aging Research Centre, G. d'Annunzio University, Chieti, Italy.
authors: Laura
authors: L
authors: Bonanni
authors: Department of Neurology & Alzheimer Centre, VU University Medical Center, Amsterdam, The Netherlands.
authors: Afina W
authors: AW
authors: Lemstra
mesh_terms: D000367:Age Factors; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D015331:Cohort Studies; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000134:cerebrospinal fluid*; D008297:Male; D000073216:Mental Status and Dementia Tests; D010300:Parkinson Disease / Q000134:cerebrospinal fluid*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D010766:Phosphorylation; D015995:Prevalence; D012737:Sex Factors; D013997:Time Factors; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; C054369:MAPT protein, human; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins
keywords: Amyloid beta-protein (1-42); Lewy body disease; biomarkers; cerebrospinal fluid; dementia with 
  Lewy bodies; tau protein